| Pharmaceutical Information |
| Drug Name |
Bicalutamide |
| Drug ID |
BADD_D00271 |
| Description |
Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor. |
| Indications and Usage |
For treatment (together with surgery or LHRH analogue) of advanced prostatic cancer. |
| Marketing Status |
approved |
| ATC Code |
L02BB03 |
| DrugBank ID |
DB01128
|
| KEGG ID |
D00961
|
| MeSH ID |
C053541
|
| PubChem ID |
2375
|
| TTD Drug ID |
D0V9BD
|
| NDC Product Code |
49711-1504; 49711-1509; 51846-1028; 62559-890; 71205-577; 0904-6019; 53104-7664; 16714-816; 60429-177; 62559-680; 43265-7195; 46014-1111; 82920-004; 54893-0001; 16729-023; 58623-0068; 63629-8308; 15308-0360; 47335-485 |
| UNII |
A0Z3NAU9DP
|
| Synonyms |
bicalutamide | 4'-cyano-3-(4-fluorophenylsulfonyl)-2-hydroxy-2-methyl-3'-(trifluoromethyl)propionanilide | Casodex | Cosudex | ICI-176334 | ICI 176334 |
|
| Chemical Information |
| Molecular Formula |
C18H14F4N2O4S |
| CAS Registry Number |
90357-06-5 |
| SMILES |
CC(CS(=O)(=O)C1=CC=C(C=C1)F)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
|
|
| ADR Term |
ADReCS ID |
ADR Frequency (FAERS)
|
ADR Severity Grade (FAERS)
|
ADR Severity Grade (CTCAE)
|
|
|
|
